{"id":"W3011210265","doi":"10.1200/jco.2006.24.18_suppl.3508","title":"Results of an interim analysis of a multinational randomized, double-blind, phase III study in patients (pts) with previously treated metastatic colorectal cancer (mCRC) receiving FOLFOX4 and PTK787/ZK 222584 (PTK/ZK) or placebo (CONFIRM 2)","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":87,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Colorectal cancer; Clinical endpoint; Irinotecan; Placebo; Bevacizumab; Interim analysis; Adverse effect; Progression-free survival; Oncology; Gastroenterology; Cancer; Chemotherapy; Randomized controlled trial; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003777092,0.000266281,0.004412715,0.0006419393,0.00004824834,0.00001074852,0.0001225927,0.000143296,0.00007850589],"category_scores_gemma":[0.001608135,0.0001519895,0.0004379312,0.000749818,0.0004139129,0.0001567758,0.00005797976,0.0004108123,1.734472e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003028491,"about_ca_system_score_gemma":0.0008150691,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003794895,"about_ca_topic_score_gemma":0.04094633,"domain_scores_codex":[0.9938591,0.0009542591,0.004028624,0.0003626368,0.0005501091,0.0002452345],"domain_scores_gemma":[0.9913868,0.003671198,0.003546519,0.0001513995,0.001058231,0.0001858209],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7268178,0.01715389,0.2259832,0.00003011347,0.007528601,0.0001816161,0.00122558,0.0001853971,0.00001833324,0.00000251342,0.00003338764,0.02083953],"study_design_scores_gemma":[0.6098204,0.04481351,0.3350146,0.0001481684,0.008642426,0.00001499848,0.0005540746,0.000783469,0.00005763564,0.000006099426,0.00004579313,0.0000988465],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.996778,0.0002765473,0.00001437961,0.000269589,0.0001689532,0.002029888,0.00005855986,0.000006075892,0.0003980541],"genre_scores_gemma":[0.9987087,0.0002441427,0.0006150883,0.0000484638,0.0001078095,0.0001090167,0.00003476839,0.00001685862,0.0001151134],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1169975,"threshold_uncertainty_score":0.9765539,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1123602644794425,"score_gpt":0.4753578184967258,"score_spread":0.3629975540172833,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}